98%
921
2 minutes
20
Background: Granulomatous mastitis is an infrequent and intricate ailment. Limited knowledge exists regarding how granulomatous mastitis progresses and its impact on disease management. We aim to prospectively capture symptoms in the general population to accurately ascertain the duration of illness and the prevalence of long-lasting symptoms.
Methods: This study reports data from 169 prospectively enrolled real-world patients with pathologically confirmed granulomatous mastitis. Patients were enrolled after screening according to the inclusion and exclusion criteria. Patients were followed-up every 2-4 weeks during treatment, then every 3-6 months (Year 1) and 6-12 months (Year 2). Outcomes included symptom resolution, disease course, and relapse. Associations between clinical variables and outcomes were assessed using appropriate statistical models, with significance defined as P<0.05.
Results: The median disease course of granulomatous mastitis was 257 days (range, 55-1,500 days), with the majority of disease regression occurring within a span of 6 months subsequent to diagnosis; 72.78% of patients preferred steroids as the initial treatment. The use of steroids was associated with a shorter disease course after adjusting for age, lump size, abscess, and sinus formation (P=0.02). Abscess formation was observed in 58.57% of patients. Notably, abscess formation during disease progression contributed to a prolonged disease course (358.67 278.24 days, P=0.03).
Conclusions: Our findings highlighted the heterogeneity of granulomatous mastitis disease course and emphasized the importance of steroid usage in shortening disease course. Avoiding abscess and sinus formation, early steroid usage during granulomatous mastitis treatment might be beneficial. These evidences provide novel insights and supports the use of steroids in patients with granulomatous mastitis for modulating their immune response. Studies are urgently needed to further elucidate the role of steroid in granulomatous mastitis management.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093171 | PMC |
http://dx.doi.org/10.21037/gs-2024-557 | DOI Listing |
Discov Oncol
September 2025
Department of Breast Surgery, The First Affiliated Hospital of Harbin Medical University, No. 23, Youzheng Street, Nangang District, Harbin, 150001, Heilongjiang, China.
Objectives: To explore the risk factors that are associated to the recurrence of granulomatous lobular mastitis (GLM) after treatment and to develop a nomogram model that can predict the risk of recurrence.
Methods: Medical records and follow-up data from GLM patients treated at our facility were retrospectively analyzed. In order to identify independent risk factors for GLM recurrence, the patients were split into groups with and without recurrence using univariate and multivariate logistic regression analyses.
JPRAS Open
September 2025
Department of Plastic and Reconstructive Surgery, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Shimotsuga, Tochigi 321-0293, Japan.
We report a rare granulomatous lobular mastitis (GLM) associated with . infection in a 41-year-old woman presenting as a subpectoral abscess. Diagnosis was delayed due to negative routine cultures and atypical presentation.
View Article and Find Full Text PDFJ Biophotonics
August 2025
Department of Breast and Thyroid Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
This study explores the use of hyperspectral imaging (HSI) to distinguish granulomatous mastitis (GM) from normal breast tissue in core-needle biopsy specimens. High-resolution spectral data were captured from paraffin-embedded sections across the 400-1000 nm range. Following preprocessing, normalization, and principal component analysis, one-way analysis of variance revealed ten wavelengths with the greatest diagnostic power.
View Article and Find Full Text PDFBreast Care (Basel)
August 2025
Massachusetts General Hospital and Harvard Medical Center, Boston, MA, USA.
Introduction: Granulomatous mastitis (GM) is a rare, benign disease characterized by painful inflammation, and abscesses typically on only one breast. Treatments include antibiotics, steroid treatments, and surgery, but there is no cure. The current study was designed to assess patient perceptions of living with the disease and what they would like physicians to know about their needs.
View Article and Find Full Text PDF